Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
Laboratory experiments with cancer cells reveal two ways in which tumors evade chemotherapy drugs designed to starve and kill them, a new study in Nature Metabolism shows.
FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults
Merus a clinical-stage oncology company developing innovative, full-length multispecific antibodies and Partner Therapeutics Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno, also called Bizengri) for the treatment of NRG1 fusion-positive cancer in the U.S.
ConcertAI announced a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.Â
The National Cancer Institute approved the following clinical research studies last month.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that navigation services are leading to better outcomes, significant cost savings for healthcare systems, and mitigation of health inequities.
The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.Â
